Spectra for:
Haruhisa KIZU, Naohiro SUGITA, Tsuyoshi TOMIMORI
Compound 1 SCUTEREPENIN-A1;(4R,11S,13R)-7-BETA-TRANS-CINNAMOYLOXY-4,6-ALPHA,13,18-TETRAHYDROXY-11,16:15,16-DIEPOXY-1-NEOCLERODANONE
Compound 1 1A (4R,7R,11S,13R)-7,15-DIACETOXY-6-ALPHA-O-TRANS-CINNAMOYL-1,16:4,18:11,16-TRIEPOXY-NEOCLERODANE
Compound 1 4A (4R,13S*,16S*)-1-BETA-CIS-CINNAMOYLOXY-6-ALPHA-HYDROXY-16-METHOXY-15,16-EPOXY-18-NEOCLERODANAL
Compound 1A (4R,11S,13R)-6-ALPHA,7-BETA,13,18-TETRA-TRANS-CINNAMOYLOXY-4-HYDROXY-11,16:15,16-DIEPOXY-1-NEOCLERODANONE
Compound 1B (4R,11S,13R)-7-BETA-TRANS-CINNAMOYLOXY-6-ALPHA,13-DIHYDROXY-4,18:11,16:15,16-TRIEPOXY-1-NEOCLERODANONE
Compound 1C (4R,11S,13R)-7-BETA-TRANS-CINNAMOYLOXY-4,18:11,16:15,16-TRIEPOXY-1-NEOCLERODANONE-13-O-METHOXY-(TRIFLUOROMETHYL)-PHENYL-ACETYLESTER
Compound 1D (4R,11S,13S)-7-BETA-TRANS-CINNAMOYLOXY-4,18:11,16:15,16-TRIEPOXY-1-NEOCLERODANONE-13-O-METHOXY-(TRIFLUOROMETHYL)-PHENYL-ACETYLESTER
Compound 2 SCUTEREPENIN-A2;(4R,11S,13R)-7-BETA-CIS-CINNAMOYLOXY-4,6-ALPHA,13,18-TETRAHYDROXY-11,16:15,16-DIEPOXY-1-NEOCLERODANONE
Compound 3 SCUTEREPENIN-B;(4R,11S,13R)-7-BETA-TRANS-CINNAMOYLOXY-2-ALPHA,4,6-ALPHA,13,18-PENTAHYDROXY-11,16:15,16-DIEPOXY-1-NEOCLERODANONE
Compound 4 SCUTEREPENIN-C1;(4R,11S,13R)-6-ALPHA-TRANS-CINNAMOYLOXY-7-BETA,13-DIHYDROXY-4,18:11,16:15,16-TRIEPOXY-1-NEOCLERODANONE
Compound 4A (4R,11S,13R)-7-BETA,13-DI-O-PARA-BROMOBENZOYLOXY-6-ALPHA-TRANS-CINNAMOYLOXY-4,18:11,16:15,16-TRIEPOXY-1-NEOCLERODANONE
Compound 5 SCUTEREPENIN-C2;(4R,11S,13R)-6-ALPHA-CIS-CINNAMOYLOXY-7-BETA,13-DIHYDROXY-4,18:11,16:15,16-TRIEPOXY-1-NEOCLERODANONE
Compound 6 SCUTEREPENIN-D1;(4R,11S*,13R*)-6-ALPHA-TRANS-CINNAMOYLOXY-1-BETA,7-BETA-DIACETOXY-11,16:15,16-DIEPOXY-18-NEOCLERODANAL
Compound 7 SCUTEREPENIN-D2;(4R,11S*,13R*)-6-ALPHA-CIS-CINNAMOYLOXY-1-BETA,7-BETA-DIACETOXY-11,16:15,16-DIEPOXY-18-NEOCLERODANAL
Compound 8 SCUTEREPENIN-E;(4R,11S*,13R*)-1-BETA-ACETOXY-7-BETA-TRANS-CINNAMOYLOXY-6-ALPHA-HYDROXY-11,16:15,16-DIEPOXY-18-NEOCLERODANAL
Compound 8A (4R,11S*,13R*)-1-BETA-ACETOXY-7-BETA,18-DI-O-TRANS-CINNAMOYLOXY-6-ALPHA,18:11,16:15,16-TRIEPOXY-NEOCLERODAN
Compound 9 SCUTEREPENIN-F1;(4R,11S*,13R*)-1-BETA-O-ACETYL-7-BETA-O-TRANS-CINNAMOYL-18-BETA-O-METHYL-6-ALPHA,18:11,16:15,16-TRIEPOXY-NEOCLERODANE-1,7,18-TRIOL
Compound 10 SCUTEREPENIN-F2;(4R,11S*,13R*)-1-BETA-O-ACETYL-7-BETA-O-CIS-CINNAMOYL-18-BETA-O-METHYL-6-ALPHA,18:11,16:15,16-TRIEPOXY-NEOCLERODANE-1,7,18-TRIOL
Compound 11 SCUTEREPENIN-G1;(4R,7R,11S,13R)-6-ALPHA-O-TRANS-CINNAMOYL-1,16:4,18:11,16-TRIEPOXY-NEOCLERODANE-6,7,15-TRIOL
Compound 12 SCUTEREPENIN-G2;(4R,7R,11S,13R)-6-ALPHA-O-CIS-CINNAMOYL-1,16:4,18:11,16-TRIEPOXY-NEOCLERODANE-6,7,15-TRIOL
Compound 13 SCUTEREPENOSIDE-A1;(4R,13S*,16S*)-1-BETA-TRANS-CINNAMOYLOXY-6-ALPHA-(BETA-D-GLUCOPYRANOSYLOXY)-16-METHOXY-15,16-EPOXY-18-NEOCLERODANAL
Compound 14 SCUTEREPENOSIDE-A2;(4R,13S*,16S*)-1-BETA-CIS-CINNAMOYLOXY-6-ALPHA-(BETA-D-GLUCOPYRANOSYLOXY)-16-METHOXY-15,16-EPOXY-18-NEOCLERODANAL
Compound 15 SCUTEREPENOSIDE-A3;(4R,13S*,16R*)-1-BETA-TRANS-CINNAMOYLOXY-6-ALPHA-(BETA-D-GLUCOPYRANOSYLOXY)-16-METHOXY-15,16-EPOXY-18-NEOCLERODANAL
Compound 16 SCUTEREPENOSIDE-A4;(4R,13S*,16R*)-1-BETA-CIS-CINNAMOYLOXY-6-ALPHA-(BETA-D-GLUCOPYRANOSYLOXY)-16-METHOXY-15,16-EPOXY-18-NEOCLERODANAL
Compound 17 SCUTEREPENIN-H;(5S,10R,13S,14S)-13-HYDROXY-7-OXO-9,11-SECO-8-ABIETEN-14,11-OLIDE
Compound 17A (5S,10R,13S,14S)-13-TRIMETHYLSILYLOXY-7-OXO-9,11-SECO-8-ABIETEN-14,11-OLIDE
Compound 17B (5S,10R,13S,14S)-7-ALPHA,13-DIHYDROXY-9,11-SECO-8-ABIETEN-14,11-OLIDE
Compound 17C (5S,10R,13S,14S)-7-ALPHA-BENZOYLOXY-13-HYDROXY-9,11-SECO-8-ABIETEN-14,11-OLIDE
Citation
| Citation | CHEM.PHARM.BULL.,46,988(1998) |
|---|---|
| Journal | Chemical and Pharmaceutical Bulletin |
| Issue | 6 |
| Volume | 46 |
| Page(s) | 988-1000 |
| Year | 1998 |
| Author(s) | Haruhisa KIZU, Naohiro SUGITA, Tsuyoshi TOMIMORI |
| Publisher | Pharmaceutical Society of Japan |
| DOI | 10.1248/cpb.46.988 |